News
Zacks.com on MSN18h
EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related ItchGSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.
We congratulate researchers at MedH who have been awarded CIMED project grants for the period 2026-2028.The following researchers at the Department ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback